News Releases | Portage Biotech

Year

07 Mar '23

Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference

WESTPORT, Conn. , March 07, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will be presenting virtually at

01 Mar '23

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

- Enrollment ongoing in IMPORT-201 Phase 1/2 trial of PORT-2 in Melanoma and Non-Small Cell Lung Cancer - Company on track to initiate Phase 1 portion of ADPORT-601 trial by end of 2Q23 - Company to Host a Key Opinion Leader Event on Targeting Adenosine Pathway in Cancer WESTPORT, Conn.

27 Feb '23

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Targeting Adenosine for Cancer: Challenging Past Assumptions with Next-Generation Small Molecule Inhibitors Thursday, March 9 th @ 10:30 am ET WESTPORT, Conn. , Feb. 27, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel

15 Feb '23

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

WESTPORT, Conn. , Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a fireside